Pfizer Inc to Review RSV Data Presented at ID Week Call Transcript
Good day, everyone, and welcome to Pfizer's analyst and investor call to review RSV data and COVID vaccine commercial update. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Sir, please go ahead.
Thanks, Chelsea, and our gratitude to all of you for joining us today.
We're very happy to be presenting some exciting RSV clinical data and provide you with an update on COVID-19.
Today, we'll be making forward-looking statements that are subject to substantial risks and uncertainties. And I'd just like to remind you that these forward-looking statements speak only as of the webcast original date, and we undertake no obligation to update or revise them in the future. You can find additional information and forward-looking statements in our SEC filings, including Forms 10-Q and 10-K, under the section labeled Risk Factors and Forward-Looking Information and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
